In our study, the CR rates of DE-DLBCL patients with Ki67 >75% and Ki67 ≤75%, receiving R-CHOP, were 64.3% and 66.7% (P= 1), and the 2-year PFS rates were 45.4% and 52.8% (P= 0.74), respectively. The gene discussed is MKI67; the disease is diffuse large B-cell lymphoma.